단백뇨를 동반한 IgA 신병증 환자들에서 데플라자코트의 신기능 보존 효과 = Renoprotective effect of deflazacort in IgA nephropathy with proteinuria

다국어 초록 (Multilingual Abstract)

Background/Aims: Steroid therapy is reported to improve the clinical outcome of IgA nephropathy. In addition, recent studies have revealed that deflazacort has fewer side effects than prednisolone. This study examined the effect of steroids and compared the clinical efficacy of deflazacort and prednisolone in patients with IgA nephropathy. Methods: We retrospectively reviewed 136 patients with biopsy-proven IgA nephropathy who received deflazacort (n=50), prednisolone (n=29), or neither (n=59), and in whom blood pressure was controlled with angiotensin converting enzyme inhibitors or angiotensin receptor blockers. The mean duration of steroid administration was 9.5±9.1 months. The initial clinical status and change in the amount of protein in the 24-hour urine were compared among the three groups. Results: The baseline characteristics (age, blood pressure, serum creatinine level, initial protein in the 24-hour urine, and creatinine clearance) did not differ significantly among the groups. The decrement of protein in the 24-hour urine was higher in the deflazacort and prednisolone groups, as compared with the control group (4.4±5.4, 4.2±1.5, and 2.1±3.1 g/day, respectively, p=0.013). The increment in the creatinine clearance was higher in the deflazacort and prednisolone groups, as compared with the control group (11.5±16.4, 12.3±26.2, and 4.8±14.91.3±0.9, respectively, p=0.009). There were no significant differences in the above parameters between the deflazacort and prednisolone groups. Conclusions: Steroid therapy reduces urinary protein excretion in IgA nephropathy, and the clinical efficacy of deflazacort and prednisolone was found to be similar. (Korean J Med 77:593-600, 2009)

참고문헌 (Reference)

1 이강욱, "신장질환에서 Angiotensinsin converting enzyme inhibitor 및 angiotensin II AT1 receptor antagonist" 57 : 489-494, 1999

2 Laville M, "Treatment options for IgA nephropathy in adults: a proposal for evidence‐based strategy" 19 : 1947-1951, 2004

3 Praga M, "Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial" 14 : 1578-1583, 2003

4 Barratt J, "Treatment of IgA nephropathy" 69 : 1934-1938, 200

5 Katafuchi R, "The improvement of renal survival with steroid pulse therapy in IgA nephropathy" 23 : 3915-3920, 2008

6 Eitner F, "Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol" 21 : 284-289, 2008

7 Markham LW, "Steroid therapy and cardiac function in Duchenne muscular dystrophy" 26 : 768-771, 2005

8 Hotta O, "Regression of IgA nephropathy: a repeat biopsy study" 39 : 493-502, 2002

9 Ballardie FW, "Quantitative appraisal of treatment options for IgA nephropathy" 18 : 2806-2809, 2007

10 Floege J, "Present and future therapy options in IgAnephropathy" 18 : 354-361, 2005

11 Cockcroft DW, "Prediction of creatinine clearance from serum creatinine" 16 : 31-41, 1976

12 D’Amico G, "Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome" 24 : 179-196, 2004

13 Rasche FM, "Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy" 19 : 465-472, 2006

14 박미나, "IgA 신병증 환자에게 있어 ACE 유전자 다형성에 따른 Angiotensin receptor blocker의 치료 효과" 대한신장학회 27 (27): 13-19, 2008

15 Ferraris JR, "Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients" 22 : 734-741, 2007

16 Ferraris JR, "Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation" 14 : 682-688, 2000

17 Shoji T, "Early treatment with corticosteroids ameliorates proteinuria, proliferative lesions, and mesangial phenotypic modulation in adult diffuse proliferative IgA nephropathy" 35 : 194-201, 2000

18 Woo KT, "Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis" 4 : 227-232, 2007

19 Lv J, "Delayed severe pneumonia in mycophenolate mofetil‐treated patients with IgA nephropathy" 23 : 2868-2872, 2008

20 Gonzalez‐Perez O, "Deflazacort: a glucocorticoid with few metabolic adverse effects but important immunosuppressive activity" 24 : 1052-1060, 2007

21 Houde S, "Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up" 38 : 200-206, 2008

22 Pozzi C, "Corticosteroids in IgA nephropathy: a randomised controlled trial" 353 : 883-887, 1999

23 Katafuchi R, "Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low‐dose prednisolone therapy" 41 : 972-983, 2003

24 Ballardie FW, "Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy" 13 : 142-148, 2002

25 Saviola G, "Compared clinical efficacy and bone metabolic effects of low‐dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12‐month open randomized pilot study" 46 : 994-998, 2007

26 Di Munno O, "Clinical equivalence between deflazacort oral drops and tablets in active rheumatoid arthritis" 18 : 140-144, 1999

27 Nakamura T, "Beneficial effects of olmesartan and temocapril on urinary liver‐type fatty acid‐binding protein levels in normo tensive patients with immunoglobin A nephropathy" 20 : 1195-1201, 2007

28 Strippoli GF, "An “evidence‐based” survey of therapeutic options for IgA nephropathy: assessment and criticism" 41 : 1129-1139, 2003

29 Grosso S, "A comparative study of hydrocortisone versus deflazacort in drug‐resistant epilepsy of childhood" 81 : 80-85, 2008